SCHEDULE: Utmost Group PLC Discloses 5.71% Stake in TriSalus Life Sciences

Utmost Group PLC has reported a beneficial ownership of 3,503,385 shares, representing 5.71% of TriSalus Life Sciences' common stock as of March 31, 2026.

Summary

• Utmost Group PLC, an insurance company, has filed a Schedule 13G indicating beneficial ownership of 3,503,385 shares of TriSalus Life Sciences, Inc. common stock.
• This ownership stake represents 5.71% of the class of securities.
• The filing date is March 31, 2026, and the reporting person is Utmost Group PLC, organized in the United Kingdom.
• Utmost Group PLC has sole voting power and sole dispositive power over these shares.
• The filing notes that compared to September 30, 2025, Utmost Group PLC's ownership decreased by more than 1% due to an increase in the company's outstanding shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting factual ownership data and a change in percentage due to share dilution, without indicating significant positive or negative performance indicators for TriSalus Life Sciences, Inc.

Positives

• Utmost Group PLC maintains a significant ownership stake of 5.71% in TriSalus Life Sciences, Inc.
• The reporting entity has sole voting and dispositive power over its entire stake, indicating clear control over its investment decisions.
• The filing is made under Rule 13d-1(b), suggesting compliance with specific SEC reporting requirements for institutional investors.

Negatives

• Utmost Group PLC's ownership percentage decreased by more than 1% compared to the previous reporting period (September 30, 2025), indicating a relative dilution of its stake.
• The decrease in ownership percentage is attributed to an increase in the total outstanding shares of TriSalus Life Sciences, Inc., which could signal dilutive financing or stock issuances by the company.

Risks

• Potential for further dilution if TriSalus Life Sciences, Inc. issues additional shares.
• Changes in TriSalus Life Sciences, Inc.'s business performance or strategic direction could impact the value of Utmost Group PLC's investment.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from TriSalus Life Sciences, Inc. It primarily reports on the current ownership status of Utmost Group PLC.

Management Comments

• "Compared to 30 September 2025, the ownership of Utmost Group PLC in the company decreased by more than 1% as a result of an increase in outstanding shares of the company."
• "By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to (J) A non-U.S. institution that is the functional equivalent of any of the institutions listed in ??240.13d 1 (b)(1)(ii)(A) through (I), so long as the non-U.S. institution is subject to a regulatory scheme that is substantially comparable to the regulatory scheme applicable to the equivalent U.S. institution(s)."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors like insurance companies to report passive stakes in public companies. The decrease in ownership percentage due to increased outstanding shares could indicate equity financing or stock-based compensation by TriSalus Life Sciences, Inc., a trend observed across various life sciences companies seeking to fund growth or operations.

Stakeholder Impact

• Shareholders of TriSalus Life Sciences, Inc.: The filing indicates a change in the ownership structure, with Utmost Group PLC's relative stake decreasing due to increased share count. This could be a precursor to further equity financing or other corporate actions.
• Utmost Group PLC: The filing confirms their investment position and highlights a change in its proportional ownership, which may influence future investment decisions.
• Creditors of TriSalus Life Sciences, Inc.: An increase in outstanding shares could potentially dilute existing equity, though the direct impact on creditors is not specified.

Next Steps

• Utmost Group PLC will continue to monitor its investment in TriSalus Life Sciences, Inc.
• TriSalus Life Sciences, Inc. may undertake further corporate actions that could affect ownership percentages.

Key Dates

Keywords

Schedule 13G, Utmost Group PLC, TriSalus Life Sciences, Beneficial Ownership, Common Stock, SEC Filing, Institutional Investor, Insurance Company, Ownership Stake